US6266622B1
(en)
*
|
1995-12-13 |
2001-07-24 |
Regents Of The University Of California |
Nuclear receptor ligands and ligand binding domains
|
DE69636677D1
(de)
|
1995-12-13 |
2006-12-14 |
Univ California |
Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
|
JP3345428B2
(ja)
|
1996-08-20 |
2002-11-18 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
合成甲状腺ホルマン組成物を使用した眼の処置
|
JP2003523498A
(ja)
*
|
1998-03-30 |
2003-08-05 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
核レセプター補助活性化因子の結合を調節するための方法及び化合物
|
KR20010042373A
(ko)
*
|
1998-03-30 |
2001-05-25 |
린다 에스. 스티븐슨 |
핵 수용체 활성을 조절하는 방법 및 화합물
|
AU2818200A
(en)
*
|
1999-03-01 |
2000-09-21 |
Karo Bio Ab |
Homology models of the glucocorticoid receptor
|
US6716452B1
(en)
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6790978B2
(en)
|
1999-03-29 |
2004-09-14 |
Novartis Ag |
Thyromimetic organic compounds
|
US6599942B1
(en)
|
1999-03-29 |
2003-07-29 |
Novartis Ag |
Thyromimetic organic compounds
|
US6516294B1
(en)
|
1999-07-01 |
2003-02-04 |
The Regents Of The University Of California |
Nuclear receptor for 1α,25-dihydroxyvitamin D3 useful for selection of vitamin D3 ligands and a method therefor
|
AU775928B2
(en)
|
1999-10-14 |
2004-08-19 |
Bristol-Myers Squibb Company |
Crystallographic structure of the androgen receptor ligand binding domain
|
US6627660B1
(en)
*
|
1999-11-16 |
2003-09-30 |
New River Pharmaceuticals Inc. |
Stabilized thyroxine compounds
|
GB0005689D0
(en)
*
|
2000-03-09 |
2000-05-03 |
Schering Ag |
Crystal
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
US20020045578A1
(en)
*
|
2000-05-22 |
2002-04-18 |
Sukits Steven F. |
Solution structure of TNFR-1 DD and uses thereof
|
US6395784B1
(en)
*
|
2000-06-07 |
2002-05-28 |
Bristol-Myers Squibb Company |
Benzamide ligands for the thyroid receptor
|
AU2001288213B2
(en)
*
|
2000-06-28 |
2005-04-14 |
Bristol-Myers Squibb Company |
Selective androgen receptor modulators and methods for their identification, design and use
|
EP1385856B1
(de)
|
2001-04-11 |
2006-02-22 |
Bristol-Myers Squibb Company |
Aminosäurekomplexe von c-arylglycosiden zur behandlung von diabetes und verfahren
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
PL377687A1
(pl)
|
2001-10-18 |
2006-02-06 |
Bristol-Myers Squibb Company |
Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą
|
WO2003043624A1
(en)
|
2001-11-16 |
2003-05-30 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
WO2003049685A2
(en)
*
|
2001-12-07 |
2003-06-19 |
The Regents Of The University Of California |
Treatment for age-related macular degeneration
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
US7470659B2
(en)
*
|
2001-12-07 |
2008-12-30 |
The Regents Of The University Of California |
Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
|
AU2003225305A1
(en)
|
2002-05-08 |
2003-11-11 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7057046B2
(en)
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
US7442554B2
(en)
|
2002-07-18 |
2008-10-28 |
Bristol-Myers Squibb Company |
Compositions and methods involving glucocorticoid receptor site II
|
EP1553937B1
(de)
|
2002-10-23 |
2010-06-02 |
Bristol-Myers Squibb Company |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
AU2003302084A1
(en)
|
2002-11-15 |
2004-06-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
WO2004052302A2
(en)
*
|
2002-12-10 |
2004-06-24 |
The Regents Of The University Of California |
A method for creating specific, high affinity nuclear receptor pharmaceuticals
|
US7302347B2
(en)
*
|
2002-12-10 |
2007-11-27 |
The Regents Of The University Of California |
Method for creating specific, high affinity nuclear receptor pharmaceuticals
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
US7459474B2
(en)
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7576121B2
(en)
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7317109B2
(en)
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
ES2524916T3
(es)
|
2003-11-12 |
2014-12-15 |
Sino-Med International Alliance, Inc. |
Compuestos heterocíclicos de ácido borónico
|
US7767828B2
(en)
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CN1882327A
(zh)
*
|
2003-11-19 |
2006-12-20 |
症变治疗公司 |
含磷的新的拟甲状腺素药
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
TW200611704A
(en)
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US7145040B2
(en)
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
US7786163B2
(en)
|
2004-07-12 |
2010-08-31 |
Forest Laboratories Holdings Limited (BM) |
Constrained cyano compounds
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
AR051446A1
(es)
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7517991B2
(en)
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
US7635699B2
(en)
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7361766B2
(en)
|
2005-01-12 |
2008-04-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7368458B2
(en)
|
2005-01-12 |
2008-05-06 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7314882B2
(en)
|
2005-01-12 |
2008-01-01 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7317024B2
(en)
|
2005-01-13 |
2008-01-08 |
Bristol-Myers Squibb Co. |
Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US20060160850A1
(en)
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006086464A2
(en)
|
2005-02-10 |
2006-08-17 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
EP2527337A1
(de)
|
2005-04-14 |
2012-11-28 |
Bristol-Myers Squibb Company |
Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
MX2007014501A
(es)
*
|
2005-05-26 |
2008-02-07 |
Metabasis Therapeutics Inc |
Tiromimeticos novedosos que contienen acido fosfinico.
|
CA2606499C
(en)
|
2005-05-26 |
2017-06-13 |
Metabasis Therapeutics, Inc. |
Thyromimetics for the treatment of fatty liver diseases
|
US7888381B2
(en)
|
2005-06-14 |
2011-02-15 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
|
TW200726765A
(en)
|
2005-06-17 |
2007-07-16 |
Bristol Myers Squibb Co |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US7632837B2
(en)
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7452892B2
(en)
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7629342B2
(en)
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7317012B2
(en)
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
WO2007002036A1
(en)
*
|
2005-06-24 |
2007-01-04 |
Thomas Lavin |
Tyroid hormone in burn and adipose deposites
|
US7795436B2
(en)
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
US7488725B2
(en)
|
2005-10-31 |
2009-02-10 |
Bristol-Myers Squibb Co. |
Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase IV and methods
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
US20100022457A1
(en)
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
ES2558517T3
(es)
|
2006-08-02 |
2016-02-04 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
US7968577B2
(en)
|
2006-11-01 |
2011-06-28 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
JP2010508358A
(ja)
|
2006-11-01 |
2010-03-18 |
ブリストル−マイヤーズ スクイブ カンパニー |
グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
JP2010524953A
(ja)
|
2007-04-17 |
2010-07-22 |
ブリストル−マイヤーズ スクイブ カンパニー |
縮合ヘテロ環11−β−ヒドロキシステロイドデヒドロゲナーゼI型阻害剤
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US20100120694A1
(en)
|
2008-06-04 |
2010-05-13 |
Synergy Pharmaceuticals, Inc. |
Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
CN101808995A
(zh)
|
2007-07-27 |
2010-08-18 |
百时美施贵宝公司 |
新颖的葡糖激酶激活剂及其使用方法
|
WO2009038974A1
(en)
|
2007-09-20 |
2009-03-26 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
WO2009058944A2
(en)
|
2007-11-01 |
2009-05-07 |
Bristol-Myers Squibb Company |
Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and /or nf- kappa b activity and use thereof
|
US8187821B2
(en)
*
|
2008-05-08 |
2012-05-29 |
University Of Utah Research Foundation |
Compositions and methods for the modulation of PGRMC1
|
PE20091928A1
(es)
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
EP2321341B1
(de)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
JP2012522015A
(ja)
|
2009-03-27 |
2012-09-20 |
ブリストル−マイヤーズ スクイブ カンパニー |
Dpp−iv阻害剤を用いて主要有害心血管事象を予防する方法
|
BRPI1015096A2
(pt)
|
2009-04-20 |
2016-05-03 |
Mitsubishi Tanabe Pharma Corp |
agonista de receptor beta de hormônio tireoideano
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
CN102686579A
(zh)
|
2009-10-09 |
2012-09-19 |
Irm责任有限公司 |
作为gpr119活性调节剂的化合物和组合物
|
PT2498758T
(pt)
|
2009-11-13 |
2018-10-23 |
Astrazeneca Uk Ltd |
Formulações de comprimido bicamada
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
CA2780938A1
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Reduced mass metformin formulations
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
WO2011130459A1
(en)
|
2010-04-14 |
2011-10-20 |
Bristol-Myers Squibb Company |
Novel glucokinase activators and methods of using same
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2014039411A1
(en)
|
2012-09-05 |
2014-03-13 |
Bristol-Myers Squibb Company |
Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists
|
EP2892897A1
(de)
|
2012-09-05 |
2015-07-15 |
Bristol-Myers Squibb Company |
Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
WO2014081660A1
(en)
|
2012-11-20 |
2014-05-30 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
EP2970384A1
(de)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonisten der guanylatcyclase und deren verwendungen
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
JP2016518357A
(ja)
|
2013-04-08 |
2016-06-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
骨格筋幹細胞を若返らせる方法および組成物
|
WO2014178892A1
(en)
|
2013-05-03 |
2014-11-06 |
Scanlan Thomas S |
Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
US9593113B2
(en)
|
2013-08-22 |
2017-03-14 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
CN103644180B
(zh)
*
|
2013-12-04 |
2015-12-30 |
苏州凯欧机械科技有限公司 |
一种卷膜机支架连接管
|
FR3023177B1
(fr)
|
2014-07-04 |
2016-08-12 |
Centre Nat De La Rech Scient (C N R S) |
Procede de preparation de co-cristaux par evaporation flash
|
US20190142963A1
(en)
|
2016-04-15 |
2019-05-16 |
Richard D. DiMarchi |
Fgf21 c-terminal peptide optimization
|
CA3044059A1
(en)
|
2016-11-21 |
2018-05-24 |
Viking Therapeutics, Inc. |
Method of treating glycogen storage disease
|
BR112019025659A2
(pt)
|
2017-06-05 |
2020-08-25 |
Viking Therapeutics, Inc. |
composições para o tratamento de fibrose
|
WO2019054514A1
(ja)
|
2017-09-14 |
2019-03-21 |
国立研究開発法人理化学研究所 |
網膜組織の製造方法
|
AU2019238090A1
(en)
|
2018-03-22 |
2020-10-08 |
Viking Therapeutics, Inc. |
Crystalline forms and methods of producing crystalline forms of a compound
|
PE20210644A1
(es)
|
2018-07-19 |
2021-03-23 |
Astrazeneca Ab |
METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
|
WO2020068661A1
(en)
|
2018-09-26 |
2020-04-02 |
Lexicon Pharmaceuticals, Inc. |
Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
|
EP3894383A1
(de)
|
2018-12-12 |
2021-10-20 |
Autobahn Therapeutics, Inc. |
Neuartige thyromimetika
|
AU2020232205A1
(en)
|
2019-03-01 |
2021-10-21 |
Autobahn Therapeutics, Inc. |
Novel thyromimetics
|
US20220170098A1
(en)
|
2019-03-13 |
2022-06-02 |
Sumitomo Dainippon Pharma Co., Ltd. |
Method for Evaluating Quality of Transplant Neural Retina, and Transplant Neural Retina Sheet
|
MA56396A
(fr)
|
2019-06-27 |
2022-05-04 |
Cytokinetics Inc |
Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
|
CN116157512A
(zh)
|
2020-09-11 |
2023-05-23 |
国立研究开发法人理化学研究所 |
包含含神经视网膜的细胞聚集体和基质的复合体及其制造方法
|
JPWO2022054924A1
(de)
|
2020-09-11 |
2022-03-17 |
|
|
TW202330906A
(zh)
|
2021-11-19 |
2023-08-01 |
國立研究開發法人理化學研究所 |
片狀視網膜組織之製造方法
|